Beril Balci Topuz

Dr. Beril Balci Topuz

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in American Journal of Case Reports
Verified
Journal Article
Open access
BTBeril Balci Topuz
Beril Balci Topuz
MSMustafa Seyyar
Mustafa Seyyar
MIMeltem Ozturk Iyilikci
Meltem Ozturk Iyilikci
GEGozde Ertunc
Gozde Ertunc
EYElif Yumuk
Elif Yumuk
EUEvren Uzun
Evren Uzun
BACKGROUND Carcinoma of unknown primary (CUP) is a rare malignancy, accounting for less than 5% of all cancers. Inguinal lymph node (LN) metastasis is an uncommon presentation, with squamous cell carcinoma (SCC) comprising a small subset of CUP cases. CASE REPORT A 65-year-old woman presented with a left inguinal mass, which was confirmed as SCC. Comprehensive diagnostics, including PET-CT, failed to identify a primary tumor. Following initial surgical resection, she experienced local recurrence and was treated with chemoradiotherapy (CRT), receiving 45 Gy to potential primary and nodal sites, followed by a 59.4 Gy boost and concurrent cisplatin. Despite an initial response to treatment, the disease progressed aggressively, leading to lung metastases and a subcutaneous metastatic nodule in the pubic region. After chemotherapy with cisplatin and 5-fluorouracil, 2 nodular lesions were identified in the right breast as new metastases - a finding not previously documented in the literature. Despite plans for a biopsy of the right breast lesions, the patient died due to respiratory complications 12 months after diagnosis. CONCLUSIONS This case of isolated inguinal LN metastasis from SCC of an unknown primary highlights the unpredictable and aggressive nature of CUP, even in subtypes typically considered favorable. The findings suggest that more aggressive multimodal treatment approaches may be warranted to manage and control potential microscopic disease effectively. Reevaluating standard treatment protocols for such presentations is essential to improve patient outcomes.

13 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BTBeril Balci Topuz
Beril Balci Topuz
Ahmet TüfekçiAhmet Tüfekçi
Ahmet Tüfekçi
SCSibel Cangi
Sibel Cangi
OYOmer Aydin Yildirim
Omer Aydin Yildirim
MYMustafa Yıldırım
Mustafa Yıldırım
Background/Objectives: Systemic inflammation, nutritional status, and immune competence have emerged as important prognostic determinants in metastatic renal cell carcinoma (mRCC). The C-reactive protein–albumin–lymphocyte (CALLY) index integrates these parameters into a single composite biomarker, yet its utility in mRCC remains insufficiently explored. This study aimed to evaluate the prognostic significance of the CALLY index in mRCC and its associations with clinicopathological features and survival outcomes. Methods: A total of 68 patients with mRCC treated between 2017 and 2024 were retrospectively analyzed. All patients received first-line VEGF–TKI therapy, and 73.5% subsequently received second-line treatment, predominantly nivolumab. The CALLY index was calculated as (albumin × lymphocyte count)/(CRP × 104), and patients were stratified using the median cut-off (0.16). Survival outcomes were assessed with Kaplan–Meier and Cox regression analyses. Discriminative performance was evaluated using Harrell’s C-index and time-dependent ROC curves at 6, 12, and 24 months. Results: Low CALLY (≤0.16) was significantly associated with shorter PFS (4 vs. 8 months, p < 0.001) and OS (9 vs. 26 months, p < 0.001). In multivariate analysis, the CALLY index independently predicted both PFS (HR = 1.91, p = 0.045) and OS (HR = 2.89, p = 0.005). Time-dependent ROC analysis demonstrated increasing discriminative strength for PFS (AUC: 0.70 → 0.95) and modest decline for OS over time (AUC: 0.83 → 0.72). CALLY also showed strong associations with IMDC risk classification and peritoneal metastasis. Conclusions: The CALLY index is a simple, cost-effective, and objective prognostic biomarker that may independently predict progression and survival in mRCC. Its complementary value to the IMDC model supports its integration into routine risk stratification and real-world clinical decision-making.

25 June 2024 in Oncology Letters
Verified
Journal Article
Open access
PDF file
BTBeril Balci Topuz
Beril Balci Topuz
FSFatma Sert
Fatma Sert
MSMurat Sezak
Murat Sezak
MSMehmet Soylu
Mehmet Soylu
DYDeniz Yalman
Deniz Yalman
SOSerdar Ozkok
Serdar Ozkok
Anal squamous cell carcinoma (SCC) treated with definitive radiotherapy (RT)/chemoradiotherapy (CRT) has shown high success rates, yet challenges such as treatment resistance and recurrence persist. The present study aimed to investigate the associations between immunohistochemical (IHC) evaluation, treatment response and prognosis in anal SCC. A retrospective cohort analysis included 42 patients with anal SCC treated at a single institution between 2006 and 2022. Human papillomavirus (HPV) status was determined, and the IHC analysis of p16, p53 and PD‑L1 expression was conducted using formalin‑fixed, paraffin‑embedded biopsies. A complete response to RT/CRT was observed in 71.4% of patients. Recurrence occurred in 38.1% of cases, of which 7.1% had local‑regional recurrence (LRR), 14.3% had distant recurrence (DR), and 16.7% had both LRR and DR. HPV positivity (71.4%) was significantly associated with p16 positivity. Lack of complete response was associated with HPV‑negative status, p16‑negative status, increased recurrence and DR. In addition, recurrence was significantly associated with p53‑positive status, and p53 positivity was significantly associated with increased LRR. PD‑L1 positivity, defined as a combined positive score (CPS) ≥1% was found in 73.8% of the patients, and exhibited significant associations with HPV positivity and p16 positivity. PD‑L1 CPS ≥ 1% was also associated with an increased LRR. Univariate analysis revealed that age <65 years, a complete response and HPV positivity were associated with increased 5‑year overall survival (OS), while a complete response, HPV positivity and p53‑negative status were associated with increased 5‑year disease‑free survival (DFS). Multivariate analysis identified that age <65 years and HPV positivity are independent prognostic factors for 5‑year OS, and a complete response and p53‑negative status are independent prognostic factors for 5‑year DFS. In conclusion, these findings suggust that the identification of HPV status and poor prognostic biomarkers at diagnosis may be used to guide personalized treatment strategies, with the combination of immunotherapy with standard CRT potentially providing improved outcomes.

20 March 2026 in BMC Cancer
Verified
Journal Article
Open access
PDF file
BTBeril Balci Topuz
Beril Balci Topuz
MIMeltem Ozturk Iyilikci
Meltem Ozturk Iyilikci
Systemic inflammation and nutritional status are increasingly recognized as prognostic determinants in glioblastoma (GBM). The CRP–albumin–lymp

2 March 2026 in The Lancet Oncology
Verified
Journal Article
Closed access
BTBeril Balci Topuz
Beril Balci Topuz
GBGenar Batur
Genar Batur
YAYavuz Anacak
Yavuz Anacak

1 January 2026 in Turkish Journal of Oncology
Verified
Journal Article
Closed access
BTBeril Balci Topuz
Beril Balci Topuz
FSFatma Sert
Fatma Sert
DYDeniz Yalman
Deniz Yalman
SÖSerdar Özkök
Serdar Özkök